NasdaqCM:SLNOBiotechs
Soleno Therapeutics (SLNO) Valuation Checked After New Q4 2025 Revenue Guidance
Fourth quarter 2025 guidance puts revenue expectations in focus
Soleno Therapeutics (SLNO) has put out preliminary unaudited revenue guidance for the fourth quarter of 2025, expecting net revenue between US$90 million and US$92 million, providing a fresh reference point for investors tracking the stock.
See our latest analysis for Soleno Therapeutics.
At a share price of US$43.56, Soleno Therapeutics has seen a 31.57% 3 month share price decline and an 11.79% 1 month share price decline, yet...